ライフサイエンスコーパス: diabetes

1 iabetes and 11.6% +/- 0.5% in adults without diabetes).

2 ributes to tendon stiffening with age and in diabetes.

3 ion of AAI and drinking duration with type 2 diabetes.

4 rgy metabolism metabolic syndrome and type 2 diabetes.

5 ickness were younger age, female gender, and diabetes.

6 survival represent potential treatments for diabetes.

7 ndations for the diagnosis and management of diabetes.

8 factor for metabolic diseases such as type 2 diabetes.

9 s with autoimmune diseases, including type 1 diabetes.

10 adults at least 60 years of age with type 1 diabetes.

11 mortality compared with individuals without diabetes.

12 ruction during the development of autoimmune diabetes.

13 ical processes such as cancer progression or diabetes.

14 gery in patients with well-controlled type-2 diabetes.

15 sulinemia precedes the development of type 2 diabetes.

16 ide a framework for personalized medicine in diabetes.

17 d chronic (damaging) associated changes with diabetes.

18 nt of AT-targeted therapeutic strategies for diabetes.

19 ption, Alternative Healthy Eating Index, and diabetes.

20 evels compared with control subjects without diabetes.

21 erning the pathways leading to IA and type 1 diabetes.

22 agon agonism in the pharmacology of treating diabetes.

23 ith AAb(-) relatives of subjects with type 1 diabetes.

24 ducted among cases with clinically diagnosed diabetes.

25 (CTR) is a drug target for osteoporosis and diabetes.

26 PC) from the bone marrow (BM) is impaired in diabetes.

27 including obesity, hypertension, and type 2 diabetes.

28 single blood glucose measurement to diagnose diabetes.

29 predictability for family history of type 2 diabetes.

30 hrough gut fermentation of fiber, in CKD and diabetes.

31 -life nutrition and the risks of obesity and diabetes.

32 sity-of-care variables, versus women without diabetes.

33 tic lymph nodes, and islets before and after diabetes.

34 hether this receptor affects BP under type 1 diabetes.

35 as compared to harmine for the treatment of diabetes.

36 e treatment of insulin resistance and type 2 diabetes.

37 re received by patients for hypertension and diabetes.

38 pancreas over a range of ages and states of diabetes.

39 esize that elafin expression correlates with diabetes.

40 ctive cells in the NOD mouse model of type 1 diabetes.

41 n SFA base) were not associated with risk of diabetes.

42 development of insulin resistance and type 2 diabetes.

43 an independent case-control study of type 2 diabetes.

44 despite optimal medical treatment for type 2 diabetes.

45 f CKD beyond MRE therapy in mice with type 2 diabetes.

46 c risk for coronary heart disease and type 2 diabetes.

47 .66 [CI, 1.07 to 2.57]) in participants with diabetes.

48 opathy (PN) is common even in the absence of diabetes.

49 olic activity, and dose necessary to reverse diabetes.

50 rmed on CGM data of 148 subjects with type-1-diabetes.

51 obtained from human donors with and without diabetes.

52 outcomes of PCI versus CABG in patients with diabetes.

53 thnicity, education level, smoking, BMI, and diabetes.

54 tabolic diseases including obesity or type 2 diabetes.

55 ent of periodontitis in patients with type 2 diabetes.

56 onsidered a marker of metabolic syndrome and diabetes.

57 diabetes in Lithuania was 3.5% (1.9% for GCK diabetes, 0.7% for HNF1A, 0.2% for HNF4A and ABCC8, 0.3%

58 o or hazard ratio, 95% confidence interval), diabetes (1.9, 1.4-3.0), panniculectomy (2.6, 1.8-3.9),

59 Similarly, longer duration of diabetes (13-25 years [AOR = 3.77; (1.05-13.5)]) and his

60 tudies included in our review, 21 focused on diabetes, 15 on adverse birth outcomes, 8 on cardiovascu

61 d July 31, 2018, 45 072 patients with type 2 diabetes (21 936 [48.7%] female; mean age 56.7 years [SD

62 thers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of children wit

63 Among individuals with type 2 diabetes, ~30% exhibit hypomagnesemia.

64 iabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of rando

65 associations of brain insulin signaling with diabetes, AD, and level of cognition.

66 iority trial in 108 participants with type 1 diabetes, aged 10-21 years and using insulin pump therap

67 human pregnancies, we found that gestational diabetes also correlates with a reduced number of T(reg)

68 itivity and its association with obesity and diabetes among adults attending a diabetes centre in the

69 3.5% +/- 0.5% (27.0% +/- 1.4% in adults with diabetes and 11.6% +/- 0.5% in adults without diabetes).

70 cohort of 389 participants included 256 with diabetes and 133 with a normal glucose tolerance.

71 also be considered for patients with type 2 diabetes and a body mass index of 30 to 35 if hyperglyce

72 Patients with a diagnosis of diabetes and a minimum of two prescriptions for diabetes

73 rient supply-demand imbalances, critical for diabetes and cancer.

74 s, including cardiovascular disease, cancer, diabetes and chronic neurological diseases.

75 se- and lipid-related biomarkers with type 2 diabetes and coronary artery disease.

76 downregulated in the corneas of humans with diabetes and diabetic rats.

77 year postpartum in women with versus without diabetes and in diabetes groups, defined by a latent cla

78 emia and body weight in patients with type 2 diabetes and obesity but have limited weight-lowering ef

79 tentially used as a prophylactic therapy for diabetes and obesity, respectively.

80 leep apnoea, and metabolic disease including diabetes and obesity.

81 for adult onset metabolic diseases, such as diabetes and obesity.

82 y novel microbial signatures associated with diabetes and support the need for further studies explor

83 ney disease (DKD) is a major complication of diabetes and the leading cause of end-stage renal failur

84 cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-renal d

85 ntrolled trial included patients with type 2 diabetes and urine albumin-to-creatinine ratio 30 to 500

86 ere used to examine the relationship between diabetes and variables associated with CRC risk and ADR.

87 ersus 120 to <130 mmHg), diabetes (versus no diabetes), and lower eGFR (<60 versus >=60 ml/min/1.73m2

88 zed as a key risk factor for obesity, type 2 diabetes, and cardiovascular diseases.

89 ous cardiomyopathies, obesity, hypertension, diabetes, and chronic kidney disease) and yielded additi

90 usting for age, sex, body mass index, type 2 diabetes, and country.

91 ngly associated with cardiovascular disease, diabetes, and hypertension.

92 miological associations among air pollution, diabetes, and lung disease.

93 Mid-life metabolic disease (ie, obesity, diabetes, and prediabetes) causes vascular dysfunction a

94 are effective drugs for treatment of type 2 diabetes, and there is consequently extensive interest i

95 DA) updates the Standards of Medical Care in Diabetes annually to provide clinicians, patients, resea

96 or TB (aOR 4.6; 95% CI: 2.5-8.7), history of diabetes (aOR 3.1; 95% CI: 1.7-5.8), current smoking (aO

97 Patients with diabetes appear to die at a higher frequency during the

98 Patients with diabetes are highly susceptible to COVID-19-induced adve

99 ens influence the development of prediabetes/diabetes are not clear.

100 in users of the newer types of drugs used in diabetes are scarce.

101 Obesity/diabetes-associated liver tumors are specifically vulner

102 Diabetes-associated organ fibrosis, marked by elevated c

103 However, other type 2 diabetes-associated SNPs that truncate SLC30A8 confer pr

104 The American Diabetes Association (ADA) updates the Standards of Medi

105 eristic curve [AUC] 0.91) and progression to diabetes (AUC 0.92) based on standard cross-validation (

106 earch tool for diagnostic imaging of obesity/diabetes, bacterial infection, and cancer.

107 ere performed in 188 patients diagnosed with diabetes before 2 years of age without a genetic diagnos

108 lins may be associated with elevated risk of diabetes beyond traditional risk factors, which needs to

109 been associated with increased incidence of diabetes, both in humans and in animal models.

110 Maternal diabetes can lead to pregnancy complications and impaire

111 nity-based, nurse-led, university-affiliated diabetes center (UDC), the JADE-Personalized (JADE-P) gr

112 in public and private outpatient clinics and diabetes centers in Hong Kong.

113 ided by physicians from specialized academic diabetes centers.

114 besity and diabetes among adults attending a diabetes centre in the UAE.Participants (N = 973) with d

115 n of genetically predicted PCOS with risk of diabetes, CHD, or stroke.

116 nditions at time of LTBI testing (e.g., HIV, diabetes, chronic kidney disease, etc.) were identified

117 32% (95% CI: 24, 39) lower hazards of type 2 diabetes compared with abstaining, respectively.

118 gulated in the kidneys of mice with comorbid diabetes compared with aged controls, whereas TMPRSS2 (p

119 support a twofold increased relative risk of diabetes compared with the general population.

120 Diabetes conferred the highest risk of progression to HC

121 a activity was demonstrated in patients with diabetes; conventional renoprotective agents did not the

122 idential urbanization level, hyperlipidemia, diabetes, coronary heart disease, migraine, hypotension,

123 comes in patients with HFrEF with or without diabetes: DAPA-HF (assessing dapagliflozin) and EMPEROR-

124 The insidious onset of type 2 diabetes delays diagnosis and increases morbidity(2).

125 glucose uptake and oxidation are reduced in diabetes despite hyperglycemia.

126 ent suppressive mechanisms may contribute to diabetes development.

127 contact residue within the epitope prevents diabetes development.

128 Duration of diabetes did not significantly correlate with pancreas S

129 otherapy with a single peptide could control diabetes driven by multiple Ags, we coencapsulated the h

130 g T2D symptoms, but its protective effect on diabetes-driven cognitive dysfunction remains elusive.

131 of VPS41 specifically in beta-cells develop diabetes due to severe depletion of insulin SG content a

132 Mean age was 74 years, with a median type 2 diabetes duration of 16 years.

133 7 [3] years; 76 [50%] were female; mean [SD] diabetes duration, 9 [5] years), 142 (93%) completed the

134 roups, defined by a latent class analysis of diabetes duration, complexity, and intensity-of-care var

135 ), and positively correlated with age, known diabetes duration, waist/hip ratio, urinary albumin/crea

136 (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results [

137 risk of Parkinson's disease in patients with diabetes exposed to thiazolidinediones (glitazones), glu

138 in women with versus without diabetes and in diabetes groups, defined by a latent class analysis of d

139 measured plasma sTNFR1 in people with type 2 diabetes (HbA(1c) >= 48 mmol/mol) at 2 hospital sites in

140 lood pressure level >90 mm Hg), uncontrolled diabetes (hemoglobin A1c level >8%), obesity (body mass

141 mplicated in the pathogenesis of obesity and diabetes; however, the mechanisms and tissue sites of ac

142 Male sex (hazard ratio [HR] 2.54, P = 0.02), diabetes (HR 2.39, P = 0.01), albumin (HR 0.35, P = 0.00

143 ng need to control systemic diseases such as diabetes, hypertension, and dyslipidaemia.

144 dex 25.4 kg/m2 (3.6), 60.1% females] without diabetes, hypertension, dyslipidemia, the metabolic synd

145 .044), controlling for age, body mass index, diabetes, hypertension, intubation, and RRT.

146 eases (hypertriglyceridemia, obesity, type 2 diabetes, hypertension, metabolic syndrome), but the mec

147 iverse negative health indicators, including diabetes, hypoalbuminemia, hyponatremia, and relative hy

148 autoimmunity (IA) and progression to type 1 diabetes in a prospective high-risk cohort.

149 The overall prevalence of MD in youth with diabetes in Lithuania was 3.5% (1.9% for GCK diabetes, 0

150 CD4(+) T cells suppressed the development of diabetes in NOD severe combined immunodeficiency mice re

151 intake related to cardiovascular disease and diabetes in patients with periodontitis.

152 istry and observed (1) a higher incidence of diabetes in people with SZ or BP and (2) higher incidenc

153 ed for age, sex, body mass index, and type-2 diabetes in the phase 2 validation cohort, the minor A a

154 nce of major mental illnesses in people with diabetes in the same large cohort.

155 ephropathy, we used streptozotocin to induce diabetes in wild-type C57BL/6 and knockout mice lacking

156 have been associated with obesity and type 2 diabetes, in epidemiological studies and studies of the

157 Diabetes incidence rates per 1000 person-years were 20.6

158 Anomalies we found in type 1 diabetes included (i) an increase of 'intermediate cells

159 ort recent findings that suggest that type 1 diabetes includes abnormalities in the exocrine pancreas

160 In patients with type 2 diabetes, increased dairy consumption to >=3 servings/d

161 Oral sulphonylureas, widely prescribed for diabetes, inhibit pancreatic ATP-sensitive K(+) (K(ATP)

162 The intersection of HIF biology with diabetes is a complex area in which many further questio

163 to reveal other monogenic atypical forms of diabetes is an important approach to gaining insight and

164 Diabetes is associated with an increased risk of colorec

165 tion of Galpha(z)-null mice from HFD-induced diabetes is beta-cell autonomous, as beta cell-specific

166 tory demyelinating polyneuropathy (CIDP) and diabetes is uncertain despite important diagnostic and m

167 these factors are altered in the context of diabetes, it is unclear what regulates localization of i

168 -2 and deleting its expression causes severe diabetes-like phenotypes without markedly causing periph

169 of insulin production, severe hyperglycemia/diabetes, lipodystrophy, hepatosteatosis, and growth ret

170 tility of these agents may not be limited to diabetes management: SGLT2 inhibitors have also shown th

171 ] age, 62.5 [9.0] years; 35% women; 70% with diabetes; median low-density lipoprotein [LDL] cholester

172 t-disease-onset administration of the type 2 diabetes medication metformin reduces mitochondrial resp

173 betes and a minimum of two prescriptions for diabetes medications between January 2006 and January 20

174 Canine diabetes mellitus (DM) affects 0.6% of the canine popula

175 The association between incidence of diabetes mellitus (DM) and living conditions has not bee

176 Patients with diabetes mellitus (DM) are characterized by enhanced thr

177 Diabetes mellitus (DM) increases tuberculosis (TB) risk.

178 r <=2.5 mum (PM2.5)) and risk of gestational diabetes mellitus (GDM), while the association between h

179 ardiovascular disease (moderate strength) or diabetes mellitus (high strength) to a lower SBP target

180 .2 years; p < 0.001) and more likely to have diabetes mellitus (p = 0.004), hypertension, hyperlipide

181 genetic variation in a mouse model of type 1 diabetes mellitus (T1DM) affects long-distance genomic i

182 ailure is a prominent complication of type 2 diabetes mellitus (T2D).

183 Patients with Type 2 diabetes mellitus (T2DM) show cognitive and mood impairm

184 GT subjects without family history of type 2 diabetes mellitus (T2DM; FH-) and 8 NGT with family hist

185 at increased risk of developing gestational diabetes mellitus and have impaired glucose tolerance wh

186 cy is rising as older maternal age, obesity, diabetes mellitus and hypertension become more common in

187 sified preventive treatment of patients with diabetes mellitus and hypertension to slow and stabilize

188 an be obtained in both preclinical models of diabetes mellitus and patients with diabetes mellitus fa

189 After excluding participants with diabetes mellitus and quality control, association of si

190 ular risk factors (body mass index, smoking, diabetes mellitus and total cholesterol).

191 odels of diabetes mellitus and patients with diabetes mellitus facilitating the bi-directional moveme

192 n primary prevention populations with type 2 diabetes mellitus is highly heterogeneous.

193 Treatment efficacy for diabetes mellitus is largely determined by assessment of

194 ion, and fibronectin retention were found in diabetes mellitus models.

195 ined by well-recognized risk factors such as diabetes mellitus or hypertension, emerging risk factors

196 People with prediabetes and diabetes mellitus spend >50% of their time outside the o

197 association between H. pylori infection and diabetes mellitus was found.

198 le-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for wor

199 ketoacidosis (DKA), a severe complication of diabetes mellitus with potentially fatal consequences, i

200 as a decision aid in individuals with type 2 diabetes mellitus without clinical atherosclerotic cardi

201 resses the interplay between obesity, type 2 diabetes mellitus, and cardiovascular diseases.

202 cally larger in patients with versus without diabetes mellitus, both subgroups derived similar benefi

203 therapies as first-line management of type 2 diabetes mellitus, considering heart failure or kidney o

204 uded CKD, men, non-White race, hypertension, diabetes mellitus, higher body mass index, higher d-dime

205 ncluding dementia, macular degeneration, and diabetes mellitus, in epidemiological studies.

206 ding cancer, cardiovascular diseases, type 2 diabetes mellitus, obesity, amnesia among other disorder

207 existent morbidities of high blood pressure, diabetes mellitus, osteoporosis, non-AIDS cancer, chroni

208 re, hypertension, 65 years of age and older, diabetes mellitus, previous stroke or transient ischemic

209 , 8967 adults <=64 years old reported having diabetes mellitus, representing 13.1 million individuals

210 Despite advances in the treatment of diabetes mellitus, the path toward endogenous renewal of

211 ered a culprit in the development of obesity/diabetes mellitus-induced cardiomyopathy.

212 une disorders and metabolic diseases such as diabetes mellitus.

213 ly changed the treatment landscape of type 2 diabetes mellitus.

214 lcohol consumption is associated with type 2 diabetes mellitus.

215 cardiovascular death in patients with type 2 diabetes mellitus.

216 crine insufficiency such as malnutrition and diabetes mellitus.

217 ease or peripheral artery disease often have diabetes mellitus.

218 tations and sulfonylurea therapy in neonatal diabetes mellitus.

219 ls or on samples obtained from patients with diabetes mellitus.

220 l heart disease; 1.74 (95% CI 1.33-2.29) for diabetes mellitus; 2.22 (95% CI 1.58-3.11) for alcohol a

221 ogenic differences exist in the two forms of diabetes mellitus; T1DM is immune mediated and T2DM is m

222 omplications or pathologies in patients with diabetes might aggravate infection course.

223 eralocorticoid Receptor Antagonist in Type 2 Diabetes (MIRAD) trial, which randomized patients to eit

224 ects of these risk factors on odds of type 2 diabetes (n = 5,042 cases) and HbA(1c) levels (n = 175,1

225 icipants and individuals with prediabetes or diabetes (n = 8/group).

226 re (lipodystrophy, n = 14), moderate (type 2 diabetes, n = 9), or mild (obesity, n = 8).

227 with increased risk of development of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), or c

228 Asymptomatic children with diabetes (odds ratio [OR], 6.5; P = 0.01), a recent cont

229 hieved an area under the curve for prevalent diabetes of 0.766 in the primary cohort (95% confidence

230 vironment interaction, whereby the effect of diabetes on PD risk appears to depend on background gene

231 ediated K/BxN model, organized insulitis and diabetes onset were unabated, despite a blocked anti-ins

232 nical parameters (GAD autoantibodies, age at diabetes onset, HbA(1c), BMI, and measures of insulin re

233 In patients with NASH and diabetes or insulin resistance, low AGER1 levels were as

234 surance, income, Charlson Comorbidity Index, diabetes or obesity when compared to no-CCY (all P > 0.0

235 ge (<65 and >=65 years) and glycemic status (diabetes or prediabetes).

236 ate, periodontally healthy, and did not have diabetes or rheumatoid arthritis in 2000.

237 having underlying immunosuppression such as, diabetes, organ transplantation, Human immunodeficiency

238 These results demonstrate that diabetes over time causes autophagy deficiency, which tu

239 polymorphisms (SNPs) associated with type 2 diabetes overlap with putative endocrine pancreatic enha

240 It also draws parallels between COVID-19 and diabetes pathology and suggests that preexisting complic

241 nd insulin secretion) to cluster adult-onset diabetes patients into five subtypes.

242 The increasing prevalence of type 2 diabetes poses a major challenge to societies worldwide.

243 ly to have a previous C-section, gestational diabetes, preeclampsia/eclampsia or be in the third trim

244 CF-related diabetes prevalence, however, steadily increased.

245 e that public health interventions targeting diabetes prevention and management would be a worthwhile

246 novo donor specific antibody, posttransplant diabetes (PTD), cardiac complications, estimated glomeru

247 A less marked trend was seen for diabetes (rate ratio, 1.55; 95% confidence interval, 1.4

248 s about how many years earlier patients with diabetes reach the 10-year cumulative risks of CRC in 50

249 Men with diabetes reached 0.44% risk at age 45 (5 years earlier t

250 d pressure at rest is typical in people with diabetes, reflects endothelial dysfunction, and increase

251 Studies have shown stress may lead to diabetes-related morbidities.

252 ns 1 year after surgery (44.6% vs. 46.6%), 8 diabetes remitters had significant reductions in WBC and

253 the ablation of genes associated with type 2 diabetes risk in genome-wide association studies.

254 All patients had neonatal/early-onset diabetes, severe microcephaly, and epilepsy.

255 d deprivation (both with a strong gradient); diabetes; severe asthma; and various other medical condi

256 rdiovascular outcome trials in patients with diabetes, SGLT2 inhibitors improve cardiovascular and re

257 n of seven novel genetic causes of monogenic diabetes, six by exome sequencing and one by genome sequ

258 to be Adv36 positive regardless of weight or diabetes status.

259 Individuals with diabetes suffering from coronavirus disease 2019 (COVID-

260 oxia, in adolescents with and without type 1 diabetes (T1D) and relate the ratio to albuminuria, rena

261 Although the etiology of type 1 diabetes (T1D) is not well understood, it is believed to

262 ion may be involved in development of type 1 diabetes (T1D), but previous epigenome-wide association

263 ment of islet autoantibodies (IA) and type 1 diabetes (T1D).

264 ance (IR) precedes the development of type 2 diabetes (T2D) and increases cardiovascular disease risk

265 Patients with type 2 diabetes (T2D) fail to secrete insulin in response to in

266 The metabolic disease type 2 diabetes (T2D) is a risk factor for TB and the mechanism

267 Type 2 diabetes (T2D) is associated with increased risk of card

268 ceptor agonist recently approved for Type-II diabetes (T2D) treatment with superior hypoglycemic effe

269 merging interest in multimorbidity in type 2 diabetes (T2D), which can be either concordant (T2D rela

270 eposits is a pathological hallmark of type-2 diabetes (T2D).

271 als robustly associated with risk for type 2 diabetes (T2D).

272 13 taxa with disrupted rhythmicity in type 2 diabetes (T2D).

273 and skin biopsies from patients with type 2 diabetes (T2DM), we revealed the implication of LXR and

274 owth and survival, but in people with type 2 diabetes the destructive effects of metabolic stress pre

275 , sex, hepatitis B e antigen serostatus, and diabetes, the presence of NASH and concomitant advanced

276 of ketone bodies, which requires people with diabetes to monitor both glucose and ketone bodies.

277 nt benefits for subgroups based on age, sex, diabetes, treatment with an ARNI and baseline eGFR, but

278 e commonly associated with insulin resistant diabetes, usually accompanied by dyslipidemia and fatty

279 od pressure (>=140 versus 120 to <130 mmHg), diabetes (versus no diabetes), and lower eGFR (<60 versu

280 nt may be efficacious in patients with HNF1A diabetes via potentiation of glucose-stimulated insulin

281 The prevalence of diabetes was 9.2% (54/589, 95%CI: 7.0-11.8%) with 52% ne

282 al of the T-cell epitopes targeted in type 1 diabetes was completed over a decade ago, providing an i

283 Diabetes was induced using the low-dose streptozotocin m

284 risk of the effect of H. pylori infection on diabetes was slightly higher than other population, CONC

285 In patients with type 2 diabetes, we also observed that intravenous infusion of

286 determined, and those in common with type 2 diabetes were identified.

287 Thirteen individuals with type 2 diabetes were studied after 4 weeks' treatment with empa

288 Akita/+ male mice with different duration of diabetes were subjected to fundus imaging using a Micron

289 both were positively associated with risk of diabetes, whereas scores of glycosylceramides, lactosylc

290 e central pathological event in type 1 and 2 diabetes, which has led to efforts to identify molecules

291 h this benefit extending to patients without diabetes who have heart failure with reduced ejection fr

292 uld be used to identify patients with type 2 diabetes who would derive benefit from fenofibrate treat

293 ting ages of CRC screening for patients with diabetes, who are at higher risk of early-onset CRC than

294 inked to obtain records of all patients with diabetes with angiographic evidence of 2- or 3-vessel CA

295 Diabetes with chronic complications, hypertension with c

296 candidemia included endocarditis, cirrhosis, diabetes with chronic complications, intravenous drug us

297 ty of life for people with type 1 and type 2 diabetes with reduced beta-cell function.

298 OP implicit time delays in individuals with diabetes without retinopathy compared with age-matched c

299 m the Look AHEAD trial (Action for Health in Diabetes) without prevalent HF were included.

300 this progression of glycemia after onset of diabetes, yet the factors that influence glycemic progre